Do you want to read an article? Please log in or register.
Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland
Eur J Gastroenterol Hepatol.
Schoepfer A, Vavricka SR, Brüngger B, Reich O, Blozik E, Bähler C
doi: 10.1097/
Inflammatory Bowel Disease
Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
Inflamm Bowel Dis.
Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D
doi: 10.1093/ibd/izz204.
Inflammatory Bowel Disease
Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy
J Crohns Colitis.
Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W
doi: 10.1093/ecco-jcc/jjz048.
Inflammatory Bowel Disease
Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients
J Crohns Colitis.
Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN
doi: 10.1093/ecco-jcc/jjy064.
RECOMMENDED
Inflammatory Bowel Disease
Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Kotwani P, Terdiman J, Lewin S
doi: 10.1093/ecco-jcc/jjaa018.
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
RECOMMENDED
Inflammatory Bowel Disease
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Gastroenterol Hepatol.
Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, Bader G, Weisshof R, Jacobs M, Gutierrez A, Ciorba MA, Christophi GP, Patel A, Hirten RP, Colombel JF, Rubin DT, Ha C, Beniwal-Patel P, Ungaro RC, Syal G, Pekow J, Cohen BL, Yarur A
doi: 10.1016/j.cgh.2020.06.050.
Inflammatory Bowel Disease
Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study
J Crohns Colitis.
Parragi L, Fournier N, Zeitz J, Scharl M, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group
doi: 10.1093/ecco-jcc/jjy040.
Inflammatory Bowel Disease
Systematic review: Clinical utility of gastrointestinal ultrasound in the diagnosis, assessment and management of patients with ulcerative colitis
J Crohns Colitis.
Smith RL, Taylor KM, Friedman AB, Gibson RN, Gibson PR
doi: 10.1093/ecco-jcc/jjz163.